Schizophrenia
is a persistent long-term brain disorder that causes severe, debilitating
psychotic episodes. Its core symptoms, auditory or visual hallucinations, are
often accompanied by fixed, false, and often paranoid beliefs, called
delusions. These two features are often combined with learning and cognitive
deficits. WHO experts have estimated that roughly 24 million people are
affected by schizophrenia worldwide.
While
the arrival of atypical antipsychotics has greatly expanded pharmacologic
treatment options over the past two decades, the current drug market does not
treat the negative and cognitive symptoms that are associated with the disease.
GlobalData expects that the growing popularity of long-acting injectable (LAI)
antipsychotics, along with the arrival of novel treatments that achieve higher
efficacy in negative- and cognitive-predominant patients, will serve to
stimulate growth in the marketplace over the forecast period. Country-specific
treatment recommendations and policy implementation will be an essential metric
for determining future mental health services in the 7MM.
For more information kindly visit: http://www.radiantinsights.com/research/geodon-schizophrenia-forecast-and-market-analysis-to-2022
Geodon
(ziprasidone; Pfizer/Meiji Seika) is a 5-HT2A/D2 antagonist, with greater
affinity for 5-HT2A than D2. With agonism at the 5-HT1A receptor, Geodon has
questionable effects on improving the negative and cognitive symptoms. The drug
has no appreciable affinity for M1 or M3 muscarinic receptors, and is
associated with low overall effects to weight and metabolic functions. With
oral and IM formulations available, Geodon can be used in acute and maintenance
treatment settings.
Scope
-
Overview of Schizophrenia, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on the
competitive landscape.
-
Detailed information on Geodon including product description, safety and
efficacy profiles as well as a SWOT analysis.
-
Sales forecast for Geodon for the top five countries from 2012 to 2022.
-
Sales information covered for the US, Germany, Italy, Spain and Japan
Reasons
to buy
-
Understand and capitalize by identifying products that are most likely to
ensure a robust return
-
Stay ahead of the competition by understanding the changing competitive
landscape for Schizophrenia
-
Effectively plan your M&A and partnership strategies by identifying drugs
with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth analysis of
Geodon performance
-
Obtain sales forecast for Geodon from 2012-2022 in the top five countries (the
US, Germany, Italy, Spain and Japan)
About
Us
Radiant Insights is a platform
for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure
market research reports, helping them in the decision making process. We have a
comprehensive collection of reports, covering over 40 key industries and a host
of micro markets. In addition to over extensive database of reports, our
experienced research coordinators also offer a host of ancillary services such
as, research partnerships/ tie-ups and customized research solutions.
For
more information visit: Radiant
Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog URL: http://www.esorics2010.org/
No comments:
Post a Comment